NMTRQ (9 Meters Biopharma) Scaled Net Operating Assets: -0.24 (As of Mar. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is 9 Meters Biopharma Scaled Net Operating Assets?

9 Meters Biopharma NMTRQ -90.00% Scaled Net Operating Assets is -0.24 as of Mar. 2023.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

9 Meters Biopharma's operating assets for the quarter that ended in Mar. 2023 was $2.37 Mil. 9 Meters Biopharma's operating liabilities for the quarter that ended in Mar. 2023 was $10.44 Mil. 9 Meters Biopharma's Total Assets for the quarter that ended in Dec. 2022 was $33.15 Mil. Therefore, 9 Meters Biopharma's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2023 was -0.24.

9 Meters Biopharma Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for 9 Meters Biopharma's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

9 Meters Biopharma Scaled Net Operating Assets Chart

9 Meters Biopharma Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.25 -1.70 -1.03 -0.13 0.19

9 Meters Biopharma Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.12 -0.18 0.51 0.23 -0.24

NMTRQ vs USRM, NOVNQ, ONCSQ: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, 9 Meters Biopharma's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

9 Meters Biopharma Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 9 Meters Biopharma's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where 9 Meters Biopharma's Scaled Net Operating Assets falls into.


9 Meters Biopharma Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

9 Meters Biopharma's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2022 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2022 )
=(Operating Assets (A: Dec. 2022 )-Operating Liabilities (A: Dec. 2022 ))/Total Assets (A: Dec. 2021 )
=(20.502-11.018)/50.174
=0.19

where

Operating Assets(A: Dec. 2022 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=33.148 - 12.646
=20.502

Operating Liabilities(A: Dec. 2022 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=30.747 - 0.051 - 19.678
=11.018

9 Meters Biopharma's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2023 )
=(Operating Assets (Q: Mar. 2023 )-Operating Liabilities (Q: Mar. 2023 ))/Total Assets (Q: Dec. 2022 )
=(2.374-10.442)/33.148
=-0.24

where

Operating Assets(Q: Mar. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=9.313 - 6.939
=2.374

Operating Liabilities(Q: Mar. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=15.612 - 0.035 - 5.135
=10.442

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of -0.24 mean?
9 Meters Biopharma (NMTRQ) has a Scaled Net Operating Assets of -0.24 as of Mar. 2023. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on 9 Meters Biopharma and its competitors.
Is 9 Meters Biopharma's Scaled Net Operating Assets too high?
9 Meters Biopharma's current Scaled Net Operating Assets is -0.24.
How does 9 Meters Biopharma's Scaled Net Operating Assets compare to USRM and NOVNQ?
9 Meters Biopharma's Scaled Net Operating Assets of -0.24 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on 9 Meters Biopharma and its competitors. 9 Meters Biopharma's current Scaled Net Operating Assets is -0.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 9 Meters Biopharma stock overvalued right now?
9 Meters Biopharma (NMTRQ) has a current Scaled Net Operating Assets of -0.24. The current Scaled Net Operating Assets is -0.24. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For 9 Meters Biopharma (NMTRQ), the current Scaled Net Operating Assets is -0.24 as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

9 Meters Biopharma Business Description

Address 4509 Creedmoor Road, Suite 600, Raleigh, NC, USA, 27612
9 Meters Biopharma Inc is a clinical-stage company pioneering novel treatments for people with rare digestive diseases, gastrointestinal (GI) conditions with unmet needs, and debilitating disorders in which the biology of the gut is a contributing factor. Its pipeline includes vurolenatide, a proprietary Phase 3 long-acting glucagon-like-peptide 1 (GLP-1) agonist for short bowel syndrome (SBS) and a robust pipeline of early-stage candidates for undisclosed rare diseases and/or unmet needs.